Clinical Trial: A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread

U.S., April 22 -- ClinicalTrials.gov registry received information related to the study (NCT07543055) titled 'A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread' on April 14.

Brief Summary: This study will test a study drug called BPX-601, a CAR-T cell product manufactured from the patient's own T-cells, to see if it can help treat advanced prostate cancer. BPX-601 is a drug that is only used in clinical studies.

The study is looking at:

* What side effects BPX-601 might cause

* What is the best dose of BPX-601

* How well BPX-601 may work to destroy prostate cancer

Study Start Date: May 14

Study Type: INTERVENTIONAL

Condition: Prostate...